FGEN: FibroGen Corp Company Value to Net Income

Corporate emblem and logo of FibroGen Inc (FGEN)

High patent barriers and stringent FDA oversight protect the business of FibroGen, Inc. (FGEN), which is collaborating with AstraZeneca and Astellas to launch cancer and anemia treatments on the global market. This price chart reflects a P/E ratio of 0.20. The company is currently battling a liquidity shortage, reducing headcount and optimizing expenses following the failure of several tests.

FGEN FibroGen Corporation: Price to Earnings Ratio in the range 07/04/2022 - 01/08/2026

Comprehensive metric breakdowns and analytics for FibroGen Corp (FGEN)

- price and consensus price forecast:
Stock Price fibrogen.com|FGEN - Consensus Target
- market capitalization information:
Market Value FibroGen, Inc.|FGEN - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share FibroGen|FGEN - Company Net Assets|Market Cap to Book Value Multiple fibrogen.com|FGEN - Company Total Assets
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio FibroGen, Inc.|FGEN - Long-Term Debt to Capital|Current Liabilities to Capital FibroGen Corporation|FGEN - Company Debts|Debt to Net Assets Ratio FibroGen, Inc.|FGEN - Company Long-Term Debts|Current Liabilities FibroGen|Interim Coverage Ratio fibrogen.com
- business earnings and investment ratios data:
FGEN - Net Profit|Expected Profit FibroGen, Inc.|FGEN - Price to Earnings Ratio|Future Price to Earnings Multiple FibroGen Inc|FGEN - Price/Earnings to Growth Ratio|Company Value to EBITDA FibroGen, Inc.|FGEN - Operating profit EBITDA|Net earnings per share for the trailing year FibroGen|FGEN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months fibrogen.com|FGEN - Earnings per share growth in current year|Projected earnings per share growth rate for next year FibroGen, Inc.
Comprehensive company analysis:fibrogen.com - FGEN
Flagship merchandise of FibroGen

For FibroGen, Inc. (FGEN), the P/E ratio serves as an indicator of market confidence amid waning revenues from core licensing assets. By analyzing the price-to-earnings trend, an investor assesses the ratio of market capitalization to net income, which allows for the timely identification of overvaluation and protects capital from risks associated with slowing cash flows within the pharmaceutical business.

Key competitors

P/E Multiple haleon.com|Price to Earnings Ratio KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Corp MENS|Ligand Corp (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|perrigo.com - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Corp - Company Value to Net Income|GLPG (Galapagos Genomics) - P/E Multiple|Market Cap to Earnings ANI Pharmaceuticals Corp ANIP|Price to Earnings Ratio MannKind Corporation (MNKD)|AMPH (amphastar.com) - Company Value to Net Income|P/E Multiple PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - Market Cap to Net Income|Theravance - P/E Multiple|Business Payback Period Aquestive Corp AQST|SCPH: P/E Multiple|TECX (Tectonic Therapeutic) - Price to Earnings Ratio|Price to Earnings Ratio Tonix Pharmaceuticals Holding Corp.|SXTC: Company Value to Net Income|Price to Earnings Ratio Eupraxia Pharmaceuticals (EPRX)|BHST - Market Cap to Earnings|P/E Multiple EXOZ (eXoZymes Inc)|Market Cap to Net Income Ratio Oramed|Entera Bio Corp - P/E Multiple|Market Cap to Earnings MindWalk Holdings, Inc.|ABVC BioPharma Inc (ABVC) - Price to Earnings Ratio|Price to Earnings Multiple CPIX|Price to Earnings Ratio QNTM|TELO: Company Value to Net Income|P/E Multiple RANI|Business Payback Period synergychc.com|Price to Earnings Ratio Rallybio RLYB|LEXX: Price to Earnings Multiple|Pulmatrix, Inc. - P/E Multiple|Pheton Holdings Ltd (PTHL) - Price to Earnings Ratio|APM (aptorumgroup.com) - Price to Earnings Ratio|LYRA - Business Payback Period|IBO (Impact BioMedical) - P/E Multiple|TNF Pharma - Market Cap to Net Income|P/E Multiple YCBD|painreform.com (PRFX) - Market Cap to Net Income Ratio|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals Inc (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|PIRS (Pieris Pharma) - Price to Earnings Multiple|Procaps Group S.A. (PROC) - Price to Earnings Ratio|Market Cap to Net Income PTPI (petrospharma.com)|QLI (Qilian International Holding) - P/E Multiple|SLRN: Company Value to Net Income|P/E Multiple TFFP